SCHEDULE 13D: Activist Investor BML Capital Opposes Ikena Oncology's Proposed Merger with Inmagene Biopharmaceuticals

BML Capital Management, holding an 8.5% stake in Ikena Oncology, Inc., has publicly declared its opposition to the proposed reverse merger with Inmagene Biopharmaceuticals, advocating instead for a wind-down of operations and cash return to shareholders.

Summary

• BML Investment Partners, L.P. and Braden M. Leonard (collectively BML) have filed a Schedule 13D, disclosing beneficial ownership of 4,090,102 shares of Ikena Oncology, Inc. Common Stock, representing 8.5% of the class.
• BML Investment Partners, L.P. holds 4,030,102 shares (8.35%), acquired using $6.7 million of working capital.
• Braden M. Leonard holds 60,000 shares, acquired using $94,800 of working capital.
• The shares were acquired for investment purposes in the ordinary course of business.
• BML sent a letter to Ikena's Board on June 16, 2025, stating that the proposed merger with Inmagene Biopharmaceuticals is not in the best interest of shareholders.
• BML plans to vote AGAINST the merger and believes other shareholders should do the same.
• BML suggests a rapid wind-down of Ikena operations and a return of all remaining cash to shareholders.
• The current share price of IKNA implies a pro-forma valuation only slightly above the combined company's estimated $175 million cash balance at close, signaling that the market believes Inmagene is worth far less than the $150 million valuation ascribed to it in the deal.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant activist investor publicly opposing a major strategic transaction (reverse merger) and advocating for a company wind-down and cash return, citing unfavorable market valuation of the merger target and difficult industry conditions.

Negatives

• BML does not believe that the proposed reverse merger with Inmagene Biopharmaceuticals is in the best interest of Ikena shareholders.
• The current share price of IKNA implies a pro-forma valuation only slightly above the combined company's estimated $175 million cash balance at close, suggesting the market believes Inmagene is worth far less than the $150 million valuation ascribed to it in the deal.
• BML believes the best course of action is a rapid winddown of Ikena operations and the return of all remaining cash to shareholders, indicating a lack of confidence in the proposed merger and current strategy.

Risks

• The proposed merger with Inmagene Biopharmaceuticals may not be in the best interest of Ikena shareholders, as argued by a significant activist investor.
• The market's implied valuation of Inmagene Biopharmaceuticals in the proposed merger is significantly lower than the $150 million valuation ascribed in the deal, potentially leading to shareholder dissatisfaction or a failed transaction.
• Current difficult conditions in the biopharma sector overall could negatively impact the company's prospects and strategic options.

Future Outlook

The reporting persons may evaluate their investment in Ikena Oncology on a continuing basis and may acquire or dispose of Common Stock depending on various factors including price, business prospects, industry conditions, and investment policies. BML plans to vote against the proposed merger with Inmagene and advocates for a rapid wind-down of Ikena operations and a return of cash to shareholders.

Management Comments

• "BML does not believe that the proposed reverse merger with Inmagene Biopharmaceuticals is in the best interest of Ikena shareholders."
• "The current share price of IKNA implies a pro-forma valuation only slightly above the combined company's estimated $175 million cash balance at close, a strong signal that the market believes Inmagene is worth far less than the $150 million valuation ascribed to it in the deal."
• "Given this, along with the current difficult conditions in the biopharma sector overall, BML believes the best course of action is a rapid winddown of Ikena operations and the return of all remaining cash to shareholders."
• "BML will be voting AGAINST the IKNA/Inmagene reverse merger and believes other holders should do the same."

Industry Context

The document highlights "current difficult conditions in the biopharma sector overall," which BML uses as a rationale for its opposition to the merger and its recommendation for a wind-down and cash return. This suggests a challenging environment for biopharma companies, potentially making strategic mergers less attractive or more scrutinized, especially if they involve valuing private entities highly.

Comparison to Industry Standards

• The document explicitly states "current difficult conditions in the biopharma sector overall," implying that the proposed merger's valuation of Inmagene at $150 million is out of step with market sentiment, as evidenced by Ikena's implied pro-forma valuation being only slightly above the combined $175 million cash balance. This suggests the market is assigning little to no value to Inmagene, contrasting sharply with the deal's internal valuation. No specific comparable companies or projects are named, but the general market sentiment for biopharma is cited as a negative factor.

Stakeholder Impact

• Shareholders: Direct impact due to the proposed merger, potential for a vote against the merger, and the activist's call for a wind-down and cash return. The valuation of their shares is directly questioned by the activist.
• Management/Employees: Potential impact from a strategic shift (merger vs. wind-down) and uncertainty regarding the company's future direction. A wind-down would significantly impact employees.
• Inmagene Biopharmaceuticals: The proposed merger is under threat due to activist opposition, potentially impacting its strategic plans.

Next Steps

• BML will vote AGAINST the IKNA/Inmagene reverse merger.
• BML believes other holders should vote against the merger.
• BML suggests a rapid winddown of Ikena operations and the return of all remaining cash to shareholders.
• The reporting persons may evaluate their investment and acquire or dispose of Common Stock in the future.

Key Dates

Recommendation

Keywords

Ikena Oncology, Inmagene Biopharmaceuticals, Reverse Merger, Shareholder Activism, Schedule 13D, BML Capital Management, Biopharma, Investment, Corporate Governance, Shareholder Value, Cash Return